SBI² 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Merck (MSD) at SBI² 2026

Nov 2–4, 2026 Boston, MA ~300 attendees Website

Merck (MSD) takes part in 1 session at SBI² 2026 in Boston. Its program compares live-cell profiling with fixed Cell Painting as a way to assess compounds in early drug discovery.

OrganizationSBI² 2026 Attendance
Merck (MSD)
Rahway, NJ
Large pharma
US pharmaceutical company, known as MSD outside North America, with medicines and vaccines in oncology, infectious disease and other areas.
Spotlight
Wed Nov 4
11:30am–11:45am
Benchmarking Live-Cell Profiling with ChromaLIVE Against Fixed Cell Painting for Early Drug Discovery
Spotlight hosted by Saguaro Biosciences
Phenotypic screening and assays

Explore the full SBI² 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full SBI² 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Merck (MSD)

Tell us what you sell and we’ll find the people at Merck (MSD) most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the Society of Biomolecular Imaging and Informatics. Submit a correction